These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparison of Kill Switch Toxins in Plant-Beneficial Halvorsen TM; Ricci DP; Park DM; Jiao Y; Yung MC ACS Synth Biol; 2022 Nov; 11(11):3785-3796. PubMed ID: 36346907 [TBL] [Abstract][Full Text] [Related]
6. Harnessing CRISPR-Cas systems for precision engineering of designer probiotic lactobacilli. Goh YJ; Barrangou R Curr Opin Biotechnol; 2019 Apr; 56():163-171. PubMed ID: 30530241 [TBL] [Abstract][Full Text] [Related]
7. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Lu TK; Collins JJ Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4629-34. PubMed ID: 19255432 [TBL] [Abstract][Full Text] [Related]
8. Engineering a CRISPR Interference System To Repress a Class 1 Integron in Escherichia coli. Li Q; Zhao P; Li L; Zhao H; Shi L; Tian P Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871091 [TBL] [Abstract][Full Text] [Related]
9. Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models. Hwang IY; Koh E; Wong A; March JC; Bentley WE; Lee YS; Chang MW Nat Commun; 2017 Apr; 8():15028. PubMed ID: 28398304 [TBL] [Abstract][Full Text] [Related]
10. Engineering conjugative CRISPR-Cas9 systems for the targeted control of enteric pathogens and antibiotic resistance. Sheng H; Wu S; Xue Y; Zhao W; Caplan AB; Hovde CJ; Minnich SA PLoS One; 2023; 18(9):e0291520. PubMed ID: 37699034 [TBL] [Abstract][Full Text] [Related]
11. Engineering Escherichia coli Nissle 1917 as a microbial chassis for therapeutic and industrial applications. Yu M; Hu S; Tang B; Yang H; Sun D Biotechnol Adv; 2023 Oct; 67():108202. PubMed ID: 37343690 [TBL] [Abstract][Full Text] [Related]
12. Midbiotics: conjugative plasmids for genetic engineering of natural gut flora. Ruotsalainen P; Penttinen R; Mattila S; Jalasvuori M Gut Microbes; 2019; 10(6):643-653. PubMed ID: 30951393 [TBL] [Abstract][Full Text] [Related]
13. Rational Design of Evolutionarily Stable Microbial Kill Switches. Stirling F; Bitzan L; O'Keefe S; Redfield E; Oliver JWK; Way J; Silver PA Mol Cell; 2017 Nov; 68(4):686-697.e3. PubMed ID: 29149596 [TBL] [Abstract][Full Text] [Related]
14. Engineering Microbial Living Therapeutics: The Synthetic Biology Toolbox. Pedrolli DB; Ribeiro NV; Squizato PN; de Jesus VN; Cozetto DA; Trends Biotechnol; 2019 Jan; 37(1):100-115. PubMed ID: 30318171 [TBL] [Abstract][Full Text] [Related]
15. Construction of recombinant E. coli Nissle 1917 (EcN) strains for the expression and secretion of defensins. Seo EJ; Weibel S; Wehkamp J; Oelschlaeger TA Int J Med Microbiol; 2012 Nov; 302(6):276-87. PubMed ID: 22748509 [TBL] [Abstract][Full Text] [Related]
16. Synthetic Cassettes for pH-Mediated Sensing, Counting, and Containment. Stirling F; Naydich A; Bramante J; Barocio R; Certo M; Wellington H; Redfield E; O'Keefe S; Gao S; Cusolito A; Way J; Silver P Cell Rep; 2020 Mar; 30(9):3139-3148.e4. PubMed ID: 32130913 [TBL] [Abstract][Full Text] [Related]
17. Genetically stable kill-switch using "demon and angel" expression construct of essential genes. Kato Y; Mori H Front Bioeng Biotechnol; 2024; 12():1365870. PubMed ID: 38481573 [TBL] [Abstract][Full Text] [Related]
18. Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation. Riglar DT; Giessen TW; Baym M; Kerns SJ; Niederhuber MJ; Bronson RT; Kotula JW; Gerber GK; Way JC; Silver PA Nat Biotechnol; 2017 Jul; 35(7):653-658. PubMed ID: 28553941 [TBL] [Abstract][Full Text] [Related]